{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:58:58Z","timestamp":1784674738403,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.drugpo.2016.11.004","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T12:01:32Z","timestamp":1481198492000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-9125","authenticated-orcid":false,"given":"Allison","family":"Matthews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Van Buskirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2016.11.004_bib0005","article-title":"Instability of the ecstasy market and a new kid on the block: Mephedrone","volume":"24","author":"Brunt","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.drugalcdep.2011.02.011","article-title":"A web-based survey on mephedrone","volume":"118","author":"Carhart-Harris","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","article-title":"Self-report among injecting drug users: A review","volume":"51","author":"Darke","year":"1998","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5042\/daat.2010.0467","article-title":"Mass-information: Mephedrone, myths and the new generation of legal highs","volume":"10","author":"Davey","year":"2010","journal-title":"Drugs and Alcohol Today"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0025","series-title":"The state of the drug problem in Europe: Annual report 2012","author":"EMCDDA","year":"2012"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0030","series-title":"European drug report: Trends and developments 2015","author":"EMCDDA","year":"2015"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0035","series-title":"Synthetic cathinones drug profile","author":"EMCDDA","year":"2016"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1360-0443.2011.03719.x","article-title":"Cognitive and subjective effects of mephedrone and factors influencing use of a \u2018new legal high\u2019","volume":"107","author":"Freeman","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/hup.2297","article-title":"Substitutional potential of mephedrone: An analysis of the subjective effects","volume":"28","author":"Kapitany-Foveny","year":"2013","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0050","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/0269881114523866","article-title":"The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample","volume":"28","author":"Lawn","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/002204261104100403","article-title":"A preference for mephedrone: Drug markets, drugs of choice and the emerging legal high scene","volume":"41","author":"McElrath","year":"2011","journal-title":"The Journal of Drug Issues"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5042\/daat.2010.0123","article-title":"Tweaking, bombing, dabbing and stockpiling: The emergence of mephedrone and the perversity of prohibition","volume":"10","author":"Measham","year":"2010","journal-title":"Drugs and Alcohol Today"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0065","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000346678","article-title":"Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationahip between mephedrone, ecstasy and cocaine","volume":"19","author":"Moore","year":"2013","journal-title":"European Addiction Research"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0070","series-title":"Australian drug trends series no. 82","article-title":"Australian trends in ecstasy and related drug markets 2012: Findings from the Ecstasy and Related Drugs Reporting System (EDRS)","author":"Sindicich","year":"2013"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0075","series-title":"Australian drug trends series no. 118","article-title":"Australian trends in ecstasy and related drug markets 2013: Findings from the Ecstasy and Related Drugs Reporting System (EDRS)","author":"Sindicich","year":"2014"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dta.310","article-title":"Social, policy, and public health perspectives on new psychoactive substances","volume":"3","author":"Sumnall","year":"2011","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0085","unstructured":"Sutherland, R., Bruno, R., Peacock, A., Lenton, S., Matthews, A., Salom, C. \u2026 Barratt, M.. Motivations for new psychoactive substance use among regular psychostimulant users in Australia. International Journal of Drug Policy (submitted for publication)."},{"key":"10.1016\/j.drugpo.2016.11.004_bib0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drugalcdep.2016.01.024","article-title":"New psychoactive substance use among regular psychostimulant users in Australia, 2010\u20132015","volume":"161","author":"Sutherland","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0095","series-title":"Global smart update volume 11: The changing nature of ecstasy","author":"UNODC","year":"2014"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugpo.2014.07.004","article-title":"Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users","volume":"26","author":"Uosukainen","year":"2015","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/02791072.2015.1048840","article-title":"Exploring the Attractiveness of New Psychoactive Substances (NPS) among experienced drug users","volume":"47","author":"van Amsterdam","year":"2015","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0110","series-title":"Drugs and the internet, issue 6","author":"Van Buskirk","year":"2016"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0115","series-title":"Drugs and the internet, issue 5","author":"Van Buskirk","year":"2015"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881113513852","article-title":"Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample","volume":"28","author":"Winstock","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1360-0443.2010.03130.x","article-title":"Mephedrone, new kid for the chop?","volume":"106","author":"Winstock","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0130","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(10)62021-1","article-title":"Mephedrone: Still available and twice the price","volume":"376","author":"Winstock","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drugpo.2016.11.004_bib0135","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1360-0443.2011.03502.x","article-title":"Mephedrone: Use, subjective effects and health risks","volume":"106","author":"Winstock","year":"2011","journal-title":"Addiction"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395916303395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395916303395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:21:38Z","timestamp":1536193298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395916303395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":27,"alternative-id":["S0955395916303395"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2016.11.004","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2016.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}